Tuesday 26 March 2019 ,
Tuesday 26 March 2019 ,
Latest News
  • Coaching centers to remain closed from Apr 1 to May 6
  • UN wants to know modalities of Rohingya relocation to Bhasan Char
  • Govt aims to reach benefits of independence to villagers: PM
  • 12 personalities, 1 organisation receive Independence Award
18 February, 2019 00:00 00 AM

FDA approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), first generic of advair diskus

drugs.com
FDA approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), first generic of advair diskus

Mylan N.V. recently announced the U.S. Food and Drug Administration (FDA) approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of Advair Diskus.

Wixela Inhub will launch in the second half of February incorporating the latest safety information required by FDA earlier this month, which prompted an amendment to the label for certain inhaled corticosteroids, including Advair Diskus and any generic versions. Wixela Inhub will be available in the 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengths for asthma patients and the 250 mcg/50 mcg strength for COPD patients.

Mylan CEO Heather Bresch commented, "Mylan remains steadfast in its efforts to expand patient access to medicines, and the FDA approval of Wixela Inhub reinforces our commitment to provide patients greater choice and lower-cost alternatives.

This milestone represents the culmination of an extensive research and development program and Mylan's more than $700 million of investment. We're proud of our Wixela Inhub team, who worked tirelessly and in close collaboration with the FDA to bring this important medicine to market and add it to our growing global portfolio of more than 700 respiratory products.

Wixela Inhub is indicated for the twice daily treatment of asthma in patients age 4 and older not adequately controlled on long-term asthma control medications or whose disease warrants initiation of treatment with both inhaled corticosteroids and long-acting beta agonists; maintenance treatment of COPD; and the reduction of COPD exacerbations in patients with a history of exacerbations. It is not indicated for the relief of acute bronchospasm.

Mylan President Rajiv Malik added, "We're pleased to offer the first FDA-approved generic of Advair Diskus, one of the leading treatments for asthma and COPD management today. We've long been confident in the science around this product and are proud of the dedication of our scientific teams to bring Wixela Inhub to market.

This complex product required a rigorous research and development program spanning over a decade and close collaboration with FDA to define the regulatory pathway. We also are proud to manufacture Wixela Inhub in our own state-of-the-art plant. This approval reinforces our ongoing commitment to increase access to more affordable treatment options for patients."

The research and development program for Wixela Inhub compared all strengths of treatment to Advair Diskus in order to meet the FDA requirements of therapeutic equivalence for a substitutable generic. In the 28-day, randomized, double-blind, placebo-controlled, parallel group study of 1,128 adult asthma patients conducted to evaluate the local (lung) bioequivalence of Wixela Inhub 100 mcg/50 mcg and ADVAIR DISKUS 100 mcg/50 mcg, the two treatments produced equivalent efficacy.

Both treatments were safe and well-tolerated with lower numbers of withdrawals due to asthma compared to the placebo group. The study included both naive and current users of Advair Diskus.

"Patients enrolled in clinical trials found Wixela Inhub easy-to-use and highly effective at controlling their asthma in a clinical bioequivalence study.

Asthma and respiratory specialists and primary care providers welcome this generic alternative to benefit many patients with asthma and COPD. " said Edward Kerwin, MD of Crisor LLC, a division of the Clinical Research Institute located in Medford, Ore. and a Clinical Investigator on the Wixela Inhub clinical program.

 

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Our cover story this week is Public Health which is the science of protecting and improving the health of communities through education, promotion of…
What is public health?

What is public health?

Public health is the science of protecting and improving the health of communities through education, promotion of healthy lifestyles, and research for…
WHO on public health and primary care

WHO on public health and primary care

Modern primary health care emerged when gross health inequalities became a global concern. The Declaration of Alma-Ata, 40 years ago, endorsed primary…
Infection prevention and control

Infection prevention and control

Infection prevention and control (IPC) is a scientific approach and practical solution designed to prevent harm caused by infection to patients and health…
Protecting workers' health

Protecting workers' health

Key facts •    In many countries more than half of workers are employed in the informal sector with no social protection for seeking…
Climate change-driven water salinity linked to hypertension in coastal Bangladesh

Climate change-driven water salinity linked to hypertension in coastal Bangladesh

MUHAMMAD NABIL Elevated blood pressure was found more prevalent in some Bangladeshi coastal communities and a new icddr,b study argues that higher water…
HIV/AIDS: Hope of a cure

HIV/AIDS: Hope of a cure

Michelle Roberts Although the finding is exciting, it is not offering up a new treatment for the millions of people around the world living with HIV.…
Brain clue to 'broken heart' syndrome

Brain clue to 'broken heart' syndrome

Your heart can be damaged after a sad event and it may be your brain's doing, experts believe. Swiss researchers have been studying people with a…
8 Ways to relieve gas pain fast

8 Ways to relieve gas pain fast

BARBARA BOLEN, PHD    Whatever gas symptoms you experience—burping, passing gas, belly pain, or bloating—while unpleasant or even…
U.S. Ambassador H. E. Earl R. Miller lauds icddr,b TB screening centre model

U.S. Ambassador H. E. Earl R. Miller lauds icddr,b TB screening centre model

The U.S. Ambassador to Bangladesh H.E. Earl R. Miller visited an icddr,b tuberculosis screening centre located in old part of the city, Dholaikhal, on…
People don't become 'adults' until their 30s, say scientists

People don't become 'adults' until their 30s, say scientists

Have you ever been told to "grow up" in your 20s or need an excuse as to why you still find cat videos on the internet really funny? Well now…
Stopping Aspirin 3 months after stent is safe, study finds

Stopping Aspirin 3 months after stent is safe, study finds

Heart patients who get a stent to prop open a blocked artery are typically put on a powerful anti-clotting drug and aspirin for a full year after their…
FDA approves Trazimera (trastuzumab-qyyp) for the treatment of Breast Cancer, Gastric Cancer

FDA approves Trazimera (trastuzumab-qyyp) for the treatment of Breast Cancer, Gastric Cancer

Pfizer Inc. recently announced the United States (U.S.) Food and Drug Administration (FDA) has approved Trazimera (trastuzumab-qyyp), a biosimilar to…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting